Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Although two growth factor receptors, EGFR and HER2, are amongst the best targets for cancer treatment, no agents targeting HER3, their kinase-defective family member, have so far been approved. Because emergence of resistance of lung tumors to EGFR kinase inhibitors (EGFRi) associates with compensa...

Full description

Bibliographic Details
Main Authors: Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman, Jeanette Clarissa Kittel, Nadege Gaborit, Gretchen Bergado Baez, Belinda Sanchez, Raya Eilam, Eli Pikarsky, Luis Paz-Ares, Yosef Yarden
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
drug resistance
EGFR
kinase inhibitor
lung cancer
monoclonal antibody
osimertinib
Online Access:https://www.mdpi.com/2072-6694/12/9/2394

Internet

https://www.mdpi.com/2072-6694/12/9/2394

Similar Items